

# Implementing Best Practices for Opioid Prescribing for Acute Dental Pain

Raymond A. Dionne, DDS, MS, PhD  
July 30, 2019



Opioid  
Response  
Network  
STR-TA



Iowa Department of Public Health  
Protecting and Improving the Health of Iowans

# Working with communities to address the opioid crisis.

- ✧ SAMHSA's State Targeted Response Technical Assistance (STR-TA) grant created the *Opioid Response Network* to assist STR grantees, individuals and other organizations by providing the resources and technical assistance they need locally to address the opioid crisis .
- ✧ Technical assistance is available to support the evidence-based prevention, treatment, and recovery of opioid use disorders.

Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.



# Working with communities to address the opioid crisis.

- ✧ The Opioid Response Network (ORN) provides local, experienced consultants in prevention, treatment and recovery to communities and organizations to help address this opioid crisis.
- ✧ The ORN accepts requests for education and training.
- ✧ Each state/territory has a designated team, led by a regional Technology Transfer Specialist (TTS), who is an expert in implementing evidence-based practices.



# Contact the Opioid Response Network

✧ To ask questions or submit a request for technical assistance:

- Visit [www.OpioidResponseNetwork.org](http://www.OpioidResponseNetwork.org)
- Email [orn@aaap.org](mailto:orn@aaap.org)
- Call 401-270-5900



# Objectives

- Understand why **opioids are bad medicine** for acute pain, patients, and society
- Learn how to target inflammation to minimize acute pain after a procedure
- Be able to individualize prescribing based on the level of pain
- How to **minimize opioid abuse related to analgesics** prescribed for orofacial pain



# Disclaimer & Conflict of Interest

**Disclaimer:** The drugs, doses and therapeutic recommendations discussed in this talk are based on the speaker's interpretation of the scientific literature and 30 years of clinical research on the management of acute pain and perioperative anxiety. **Clinical application** of this information requires knowledge of the information contained in the **FDA labeling** of the specific drugs, careful review of the individual **patient's medical history** and current **medications**, appropriate monitoring of the response to the drug(s) and doses administered, and **skill in the prevention and management of adverse reactions that occur with all drugs with variable but finite prevalence**.

**Conflict of Interest Statement:** The speaker is on the faculty of the ECU School of Dental Medicine and Brody School of Medicine, serves on the scientific advisory board of Charleston Laboratories and the GSK Global Pain Advisory Board and is a consultant to Rileto Pharmaceuticals. He is also on the editorial board of the Compendium, Applied Clinical Pharmacology and Toxicology, and Clinical Pharmacology and Translational Medicine.





# **Analgesic Prescribing in the Opioid Overdose Era**

# Opioids: Bad Medicine for Dental Pain, Patients and Society

- **Current status of the opioid overdose crisis in the US**
- **Risk factors for opioid prescribing contributing to substance abuse**
- **Dental profession leadership in fighting substance abuse:**
  - **Opioid stewardship – avoid use of irrational analgesic combinations**
  - **Recognizing inherent vulnerability for substance abuse**
  - **Early prevention through patient education in the dental office**
- **Beware the potential consequences of inappropriate opioid prescribing**



# Association of Opioid Prescriptions From Dental Clinicians for US Adolescents and Young Adults With Subsequent Opioid Use and Abuse

Alan R. Schroeder, MD; Melody Dehghan, BA; Thomas B. Newman, MD, MPH; Jason P. Bentley, PhD; K. T. Park, MD, MS

Supplemental content

JAMA Intern Med. doi:10.1001/jamainternmed.2018.5419 Published online December 3, 2018.

Table 2. Outcomes in the Opioid-Exposed and Opioid-Nonexposed Cohorts

Outcome (N = 44 664)	Cohort, No. (%)		P Value <sup>a</sup>	Adjusted Absolute Risk Difference, % (95% CI) <sup>b</sup>
	Opioid-Exposed (n = 14 888)	Opioid-Nonexposed (n = 29 776)		
Opioid prescription at 90 to 365 d	1021 (6.9)	30 (0.1)	<.001	6.8 (6.3 to 7.2)
>1 Opioid prescription	387 (2.6)	3 (0.01)	<.001	2.5 (2.2 to 2.7)
At least 1 diagnosis of opioid abuse in subsequent 365 d	866 (5.8)	115 (0.4)	<.001	5.3 (5.0 to 5.7)
Site of encounter <sup>c</sup>				
Office visit	790 (5.3)	97 (0.3)	<.001	4.9 (4.5 to 5.3)
Emergency department visit	25 (0.2)	24 (0.1)	.005	0.1 (0.02 to 0.2)
Hospitalization	74 (0.5)	79 (0.3)	<.001	0.2 (0.1 to 0.4)
Most common diagnoses of opioid abuse <sup>c</sup>				
Opioid type dependence, unspecified	602 (4.0)	66 (0.2)	<.001	3.8 (3.5 to 4.1)
Poisoning by opium (alkaloids), unspecified	82 (0.6)	8 (0.03)	<.001	0.5 (0.4 to 0.6)
Opioid abuse, unspecified	51 (0.3)	25 (0.08)	<.001	0.3 (0.2 to 0.4)
Death	1 (0.007)	1 (0.003)	.62	0.003 (−0.002 to 0.005)

<sup>a</sup> P value obtained from  $\chi^2$  analysis.

<sup>b</sup> Adjusted for race/ethnicity and previous nonopioid substance abuse.

<sup>c</sup> Some patients had more than 1 site of encounter or diagnosis of opioid abuse.




# Opioid Overdose Epidemic 2019

- Leveling off in national death rate but little sign of improvement in some parts of the country: **20% increase in opioid overdose deaths in NC**
- **Decreased life expectancy** in US due to opioid overdoses
- Overall drug overdose mortality has grown **exponentially** over the past 40 years Jalal et al. Science 2018
- Victims not just those who OD
- **'Economic cost of the opioid crisis: \$1 trillion and growing faster'** CNBC.com, 2/13/2018
- Drug rehabilitation **15 - 20% recovery**



# Opioid drug abuse often starts with an opioid prescription drug



Used both,  
**analgesics  
used first**


Heroin only

Pain Management and the Opioid Epidemic  
National Academy of Science July 2017 11



# Substances\* Contributing to Unintentional Medication, Drug, and Alcohol Poisoning Deaths

North Carolina Residents, 1999-2016



\*These counts are not mutually exclusive. If the death involved multiple drugs it can be counted on multiple lines.


Source: N.C. State Center for Health Statistics, Vital Statistics-Deaths, 1999-2016, Unintentional medication, drug, alcohol poisoning: X40-X45 with any mention of specific T-codes by drug type (Commonly Prescribed Opioids, Heroin, Other Synthetics, Benzodiazepines, Cocaine, Alcohol, and Psychostimulants). Analysis by Injury Epidemiology and Surveillance Unit

North Carolina  
Injury & Violence  
PREVENTION Branch



# Medication or Drug Overdose Deaths by Intent

## NC Residents, 1999-2016




Source: N.C. State Center for Health Statistics, Vital Statistics-Deaths, 1999-2016  
 Medication or drug overdose: X40-X44, X60-X64, Y10-Y14, X85.  
 Analysis by Injury Epidemiology and Surveillance Unit

North Carolina  
 Injury & Violence  
 PREVENTION Branch



# Exponential increase in mortality rate due to substance abuse over 38 years




Jalal H et al, Science 361; 2018



# With unprecedented availability of cheap heroin and fentanyl...

## MORE PEOPLE ARE DYING



North Carolina  
Injury & Violence  
PREVENTION Branch



# Percent of Opioid Overdoses Positive for Heroin, Fentanyl, and/or Fentanyl Analogues\*\*

Office of Chief Medical Examiner Investigated Deaths, 2010-2017\*



\*2017 data are preliminary and subject to change


Source: NC Office of the Chief Medical Examiner (OCME) and the OCME Toxicology Laboratory, 2010-2017 Q4

\*\*Fentanyl analogues include: Acetyl fentanyl, Butyrylfentanyl, Furanylfentanyl, Fluorofentanyl, Acrylfentanyl, Fluoroisobutyrylfentanyl, Beta-Hydroxythiofentanyl, Carfentanil. The presence of a drug does not necessarily indicate that it was attributed to the cause of death.

North Carolina  
Injury & Violence  
PREVENTION Branch



# Self-reported Lifetime Use of Substances among North Carolina High School Students



\* Question not asked

Source: NC Department of Public Instruction, NC Youth Risk Behavioral Survey (YRBS), 2001-2017  
Analysis: Injury Epidemiology and Surveillance Unit

North Carolina  
Injury & Violence  
PREVENTION Branch



# Little Progress After A Century of Opioid Drug Research

Placebo response  
Category scales

Clinical trials  
methodology

Opiate receptor  
Aspirin MOA  
**Dental model**

Endogenous pain  
inhibitory system

Gender,  
Genetics  
Imaging

Pharmacogenomics  
Gene expression  
Proteomics  
**Opioid OD epidemic**

PRO's  
Phenotyping  
**Personalized  
medicine**

Milestones

Major Drug Classes

1950's

narcotics  
aspirin  
adjuncts

1960's

opiates  
aspirin  
acetaminophen  
adjuncts

1970's

**opioids**  
**NSAIDs**  
**acetaminophen**  
**adjuncts**

1980's

opioids  
NSAIDs  
acetaminophen

1990's

coxibs  
antidepressants  
anticonvulsants  
opioids  
NSAIDs  
acetaminophen

2000's

**NSAIDs**  
**opioids**  
**acetaminophen**  
**gabapentin**

beyond

**NIH Director  
predicts  
non-addictive  
analgesic in 5  
years**

NEJM 1980 Letter: *'despite the widespread use of narcotic drugs in hospitals, the development of addiction is rare in medial patients with no history of addiction.'*



Cited in 608 times as evidence of safety

Washington Post June 2, 2017




# Risk Factors Related to Opioid Prescribing: Wide Variability in Pain and Analgesia Across Patients

## Experimental Pain



## Clinical Pain (3<sup>rd</sup> Molar Extraction)




**Variability** in *self-administered morphine* dose for post-general surgery pain: 1 – 48 mg  
mean dose = 13.3 mg

*Aubrun et al. Anesthesiology 2003; 98:1415*




*Kim H et al., Pain 2004*


# Cumulative Dose-Response Curve Masks Individual Responses



$$\text{Therapeutic Index: } \frac{ED_{99}}{ED_{50}} = \frac{200}{100} = 2$$



# Conceptual Basis for Pain Variability at the Level of Individual Patients



# GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN

## IMPROVING PRACTICE THROUGH RECOMMENDATIONS

CDC's *Guideline for Prescribing Opioids for Chronic Pain* is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.

## DETERMINING WHEN TO INITIATE OR CONTINUE OPIOIDS FOR CHRONIC PAIN

**1** Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.

**2** Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how opioid therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.

**3** Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.

### CLINICAL REMINDERS

- Opioids are not first-line or routine therapy for chronic pain
- Establish and measure goals for pain and function
- Discuss benefits and risks and availability of nonopioid therapies with patient



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention

LEARN MORE | [www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)

- Opioids are not first-line or routine therapy for chronic pain
- When opioids are needed for acute pain, prescribe no more than needed
- Do not prescribe ER/LA opioids for acute pain
- Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed.



# FDA to issue pain management guidelines

BY JENNIFER GARVIN

*Silver Spring, Md.* — The Food and Drug Administration announced Aug. 32 that it will develop prescribing guidelines in an effort to give health care providers "the most current and comprehensive guidance on the appropriate management of pain."

To do this, the FDA said it has awarded a contract to the National Academies of Sciences, Engineering, and Medicine to develop evidence-based guidelines for "appropriate opioid analgesic prescribing for acute pain resulting from specific conditions or procedures."

"The primary scope of this work is to understand what evidence is needed to ensure that all current and future clinical practice guidelines for opioid analgesic prescribing are sufficient, and what research is needed to generate that evidence in a practical and feasible manner," said FDA Commissioner Scott Gottlieb, M.D., in prepared remarks.

Dr. Gottlieb said the FDA plans to re-examine how opioids are being prescribed since "many common, acute indications" could be treated with "just a day or two of medication rather than a 30-day supply, which is typically prescribed."

which the ADA is a supporting organization.

In March the ADA adopted interim policy on opioid prescribing that supports prescription limits and mandatory continuing education for dentists.

The policy is believed to be one of the first of its kind from a major health professional organization. During a meeting with the National Institute on Drug Abuse and National Institute of Dental and Craniofacial Research, leadership from the two NIH branches praised the ADA for the policy.

ADA President Joseph P. Crowley and Executive Director Kathleen T. O'Loughlin met with Commissioner Gottlieb in March.

The two shared several opioid articles published in the April 2018 edition of the Journal of the American Dental Association, including a systematic review that found various non-steroidal anti-inflammatory drugs, alone or in combination with acetaminophen, were found to be as effective, if not more effective at managing acute dental pain and produced less side

effects than opioids.

For more than 10 years, ADA education efforts on this issue have included free quarterly webinars.

The 2018 offerings included information on providers' role in helping DDA prevent prescription drug abuse, inter-professional approaches to addressing opioid abuse and managing dental pain in adolescents and adults.

Follow all of the opioid-related ADA efforts at [ADA.org/opioids](http://ADA.org/opioids). ■

—[jgarvin@ada.org](http://jgarvin@ada.org)

‘The primary scope of this work is to ensure that all current and future clinical practice guidelines for opioid analgesic prescribing are sufficient...’

‘Dr. Gottlieb said that...many common, acute indications could be treated with just a day or two of medication rather than a 30-day supply.’





# **Steps to Optimize Analgesia, Minimize Side Effects and Lower the Risk of Opioid Abuse**

# 1. Target the Inflammatory Etiology of Acute Dental Pain

- ***Nociceptive - transient, protective/prevent further tissue damage***
- ***Inflammatory – to protect the injured tissue***
- ***Neuropathic – peripheral NS damage***
  - Diabetic neuropathy
  - AIDS
  - Chemotherapy - induced peripheral neuropathy
- ***Functional – abnormal processing or function of CNS***
  - Fibromyalgia



# Inflammatory Pain


*Blocked by NSAIDs*

*Minimizes*


*Resulting in Much Less*

*Produces Little or No*


*'Slight' Pain after LA offset, instead of*



# Microdialysis Methods to Evaluate Relationship Between Acute Pain and COX-Mediated PGE<sub>2</sub> at the Surgical Site





Impacted  
Third  
Molars




# NSAIDs Produce Analgesia by Lowering PGE<sub>2</sub> Levels at the Site of Injury


NSAID administration after onset of inflammation and pain




# NSAID Prior to Tissue Injury Suppresses COX




# Acetaminophen COX-2 Inhibition



# Suppression of Both COX-1 and COX-2 To Optimize Efficacy






**Toxicity of NSAIDs are Based on Their Selectivity For COX1 or COX2**




# Adverse effects – GI/Cardiovascular Toxicity





## Adapted from:

J. Barden,<sup>1</sup> J. E. Edwards,<sup>2</sup> H. J. McQuay,<sup>3</sup> P. J. Wiffen<sup>4</sup> and R. A. Moore<sup>5</sup>

© British Dental Journal 2004; 197: 407–411



# Little additive analgesic effect in combination with an NSAID



# 2. Prescribe Opioids Less Prone to Abuse

## Codeine

- Usually combined with aspirin or acetaminophen due to weak analgesic activity
- Codeine converted to morphine by P450 isozyme CYP2D6
  - About 10% of codeine dose will be converted to morphine




FIGURE 2 - Biotransformation of codeine, with the consequent release of morphine *in vivo*.

## Oxycodone (Oxycontin)

Deaths linked to opioid abusers after pills crushed and dissolved for IV administration

Combined with acetaminophen (Percocet)

## Hydrocodone

Acetaminophen combination (Vicodin)

Ibuprofen combination (Vicoprofen)



# Individual Variability in Drug Abuse is Heritable



The **addictions are moderately to highly heritable**, which is paradoxical because **these disorders require use**; a choice that is itself modulated by both genes and environment. **The addictions are interrelated and related to other psychiatric diseases by common neurobiological pathways**, including those that modulate reward, behavioral control and the anxiety or stress response.

Goldman D et al. Nature Reviews/Genetics 2005


**Outcome from  
Short Course of  
Opioid Abuse  
Associated with  
Heritability**



# Mood Alteration and Reward Properties of Opioids



- **Overlapping neural systems for analgesia, physical dependence and opioid reinforcement**
- **Increased DA release is powerfully rewarding**
- **Opiates increase DA release in the Nac**
- **MOR are present post-synaptically on GABAergic neurons**
- **Reinforcing properties of opioids mediated through inhibition of local GABAergic neuronal activity**



'the dark side of pleasure is addiction'  
'brain imaging shows that **heroin**, **orgasm** and **fatty foods** all activate the same pleasure circuits'

# How Can We Minimize Opioid Abuse Related to Analgesics Prescribed for Orofacial Pain?

~ **10 billion dosage units** dispensed annually make opioids among the most frequently prescribed medications in US

**Opioids prescribed for therapeutic purposes may also result in:**

**Diversion** – excess pills are given (diverted) to family members, friends, or sold on the streets.

**Dependence** – may be **physical** (body responds negatively when the drug is discontinued following chronic use) or **psychological** (loss of ability to make sound decisions about what is right or wrong related to their drug use)

**Addiction** – physical and psychological dependence characterized by **neurochemical and molecular changes in the brain**

**Death due to overdose**

1.Oakley M, O' Donnell J, Moore PA. The Rise in Prescription Drug Abuse: Raising Awareness in the Dental Community. Compendium. 2011;32(6):14-24.

2.National Institute on Drug Abuse. Media Guide. The Basics: The Science of Drug Abuse and Addiction. Available at: <http://www.drugabuse.gov/mediaguide/scienceof.html> .



# 3. Minimize Diversion

Most commonly prescribed opioid amount is 20 doses and a 3-day supply.

## What Happens to These Drugs?

- Used in totality as prescribed
- Stored “for a rainy day”
- Sold on the street
- Given to friends/family

**< Half of opioids prescribed for pain after oral surgery were used, only 5 patients used all of the prescribed pills (N=28)**

Maughan BC et al. Drug and Alcohol Dependence 2016

**Extrapolates into millions of pills available for diversion after dental procedures**



# 4. Prescribe Analgesics Based on Scientific Evidence not Tradition

## Established prescribing behaviors

- Efficacy of APAP-opioids established in 1970's, **before NSAIDs introduced**
- Improved clinical analgesic research (Cooper & Beaver 1976)
- **NSAIDs efficacy and safety >> opioid combinations**

## Misperception of DEA Scheduling of Opioids

- Schedule 2 drugs have greater ***abuse potential***, not efficacy

## Placebo response contribution to analgesic efficacy

- Placebo response is 30-40% for simple extractions
- **Misperception that Rx analgesics are more potent than OTC analgesics**

## Prescribing for Most Severe Outcome

- Often prescribe **to manage the worse case scenario**
- May benefit 20% with worse pain, but not needed for the other 80%

## Unfounded Expectations of APAP Efficacy

- **Maximum dose reduced** from 1000 mg to 650 mg

## Patient Expectations and Demands

- Not providing an opioid can be perceived **as less than optimal treatment**
- **Need to educate patients that NOT providing an opioid is the best treatment**

*Why Do We Prescribe Vicodin?* Moore, Dionne, Cooper, Hersh: JADA July 2016




# 5. Recognize that Pain Relief ~ Abuse Potential for Most Opioids

Drugs	Response	
	Abuse Liability	Maximal Pain Relief
<b>Strong Opioid Agonists</b> Morphine, meperidine, fentanyl, alfentanil, hydromorphone, levorphanol, methadone, oxymorphone, remifentanyl, sufentanil	High	High
<b>Moderate to Strong Agonists</b> Codeine, hydrocodone, oxycodone	Moderate	Low to Moderate
<b>Agonist/ Antagonists</b> Buprenorphine, butorphanol, nalbuphine, pentazocine	Low	Moderate to High



# Mu Opioid Receptors: Combined Analgesia and Toxicity



**Respiratory depression**  
**Sedation**  
**Physical dependence**  
**Constipation**  
**Miosis**

Table 4. Acute adverse events observed in children for medications or medication combinations.<sup>18</sup>

MEDICATION OR MEDICATION COMBINATION, DOSE	STUDIES, NO.	ACUTE ADVERSE EVENTS REPORTED, NO.	STUDY PARTICIPANTS, NO.	ACUTE ADVERSE EVENTS, %
Codeine, 2 milligrams/kilograms	1	74	56	132
Oxycodone, 0.2 mg/kg	2	69	73	95
Morphine, 0.5 mg/kg	2	84	140	60
Ibuprofen, 10 mg/kg, and Oxycodone, 0.1 mg/kg	1	8	22	36
Acetaminophen Plus Codeine, 1 mg/kg	3	94	368	26
Ibuprofen, 10 mg/kg, and Codeine, 1 mg/kg	2	52	209	25
Ibuprofen, 10 mg/kg	9	74	510	15
Naproxen, 20 mg/kg	1	4	41	10
Ketoprofen, 40 mg	1	2	33	6
Tramadol, 2 mg/kg	1	3	67	4
Acetaminophen, 15 mg/kg	6	10	260	4



## 6. Consider Atypical Centrally-Acting Analgesics if an Opioid is Indicated

### Tramadol (Ultram®)


- Moderate-strong analgesic
- Agonist at mu receptors and blocks uptake of NE and 5-HT so spinal pain processing is less efficient
- **Minimal potential for dependence or abuse**
- **Minimal potential for respiratory depression**
- Effects partially blocked by naloxone
- Metabolized by CYPs (CYP2D6 and others) to 5 different metabolites
  - Desmethyltramadol is 200 times more potent
  - Depending on genetics analgesic effects can either increase or decrease

**FDA states that tramadol is contraindicated < 12 years of age for pain**  
**Can be prescribed over the phone or electronically per CVS**  
**Not listed in STOP Act provisions to limit opioids misuse**



# 7. Recognize that Naloxone (Narcan) for Opioid Reversal Does not Treat Substance Abuse

## Antagonist at mu and kappa receptors



**NARCAN** (naloxone HCl)  
NASAL SPRAY 4mg

# POWERLESS

## TO HELP REVERSE AN OPIOID OVERDOSE

**FIRST and ONLY FDA-approved nasal naloxone for emergency treatment of an overdose caused by an opioid\***

- Needle-free
- Ready-to-use
- 4 mg concentrated dose

Not a substitute for emergency medical care. Repeated doses may be necessary.


**Please see Indications and Important Safety Information**

\*such as fentanyl, heroin, Percocet®, etc.

INDICATIONS AND IMPORTANT SAFETY INFORMATION ▾



# Emergency Department Opioid Overdose Visits & EMS Naloxone Administration, 2011-2016†



†ICD9 to ICD10 coding changed in October 2015. Impact on surveillance is unclear.

Naloxone administration alone by EMS does not necessarily equate to an opioid overdose.


Source: NC DETECT (statewide ED data), N.C. Division of Public Health and UNC Carolina Center for Health Informatics (CCHI); EMSpic- UNC Emergency Medicine Department, N.C. Office of Emergency Medical Services (OEMS), 2011-2016

North Carolina  
Injury & Violence  
PREVENTION Branch




# 8. Use the PAIN Management Paradigm

- P = **Prevention**
- A = **Anti-inflammatory**  
**Acetaminophen**  
**Anesthetics**
- I = **Individualize**
- N = **Narcotics (opioids)**



***A milligram of prevention is better than a pound of rehabilitation***

# Therapeutic Strategies




# 9. Use Acetaminophen for Additive Analgesia

- Inhibits Prostaglandin Hydroperoxidase
- Metabolites of acetaminophen act on TRPA1-receptors in the spinal cord to suppress the signal transduction from the superficial layers of the dorsal horn, to alleviate pain.
- One metabolite (AM-404) inhibits Na channels and the reuptake of endogenous cannabinoids



# Additive Preemptive Analgesia for NSAID and Long-Acting Local Anesthetic




Dionne et al. 1984




# Preventive Effects of Postop Pain Control

## Immediate Postop. Pain



\*  $P < 0.001$  Bupivacaine drug effect, 2-ANOVA

## Pain at 48 Hours




\*  $P < 0.05$  Bupivacaine drug effect, 2-ANOVA




# Dual COX-1/COX-2 Suppression Prevents Central Sensitization

Pain Postoperatively



Pain at 24 and 48 hr



# 10. Individualize Prescribing for Acute Pain to Minimize Opioid Misuse or Abuse Based on Procedure, Pain Level and Validated Drugs and Combos

## Mild Pain

OTC ibuprofen, naproxen or ketoprofen as needed

## Moderate Pain

Ibuprofen 400-600 mg every 4-6 hours by the clock for first 48-72 hours, not to exceed maximum recommended daily dose. As needed until pain subsides

**Dionne, Gordon, Moore: Compendium 2016; 37:372-378**



# Individualize Prescribing

## Moderately Severe Pain

Prescription dose of NSAID administered prior to the procedure or immediately afterwards

Administration of long-acting local anesthetic 0.5% bupivacaine with epinephrine for procedural anesthesia and postoperative analgesia

Postoperative administration of prescription dose of NSAID administered by the clock for 48-72 hours combined with administration of acetaminophen 600/650 mg by the clock; the two medications can be given concurrently or alternated to maintain blood levels of both medications

## Severe Pain

Provide a prescription of an opioid drug in combination with acetaminophen to be filled and administered only if needed for pain not relieved by regimen for Moderately Severe pain.

Example: 2 tablets of 325 mg acetaminophen plus 37.5 mg tramadol (Ultracet) every 4-6 hours for pain, not to exceed 8 tablets every 24 hours

***NB: Separate dosing of 600/650 mg acetaminophen needs to be discontinued***



# Comparison of Conventional Approach to Targeted Strategies


	<u>Opioid Combinations</u>	<u>Preventive/Additive/Adaptive</u>
<b>Analgesia</b>	++	+++
<b>Adverse Effects</b>	+++	+
<b>Abuse Potential</b>	+++	0 (without opioid) + (with tramadol) ++ (with oxycodone or hydrocodone)
<b>Overdose Risk</b>	++	0 (without opioid) + (with tramadol) ++ (with oxycodone or hydrocodone)

Relative effects based on well-established pharmacology of drug classes and specific agents in Table 1



# How to identify drug seeking behavior?

- **Drug being requested:** opioids, benzodiazepines, methylphenidate, dexamphetamine, anabolic steroids, anti-psychotic drugs
- **Asking for a specific drug** by name or brand name
- **Claiming allergy** to alternative drugs
- Doctor shopping
- **Anger** when questioned about symptoms such as pain
- **Unscheduled** clinic visits for **refills**
- Unauthorized **dose escalation**
- Claiming to be **unable to afford dental work** needed to manage dental pain
- **Multiple visits** for the same complaint
- **More concerned** about the **drug** than medical/dental **problem**



# Example of Successful Intervention Effort to Minimize Problematic Clinical Practice



## Original Contributions

### Cover Story

# Opioid prescribing practices from 2010 through 2015 among dentists in the United States

What do claims data tell us?

Niodita Gupta, MD, MPH, PhD; Marko Vujicic, PhD; Andrew Blatz, MS

## ABSTRACT

**Background.** Dentists wrote 6.4% of all opioid prescriptions in the United States in 2012. The purpose of this study was to examine opioid prescription rates, dosage of opioids prescribed, type of opioid drug prescribed, and type of dental visit at which dentists prescribe opioids.

**Methods.** The authors used the 2010 through 2015 Truven Health Marketscan Research databases and the Prescription Drug Monitoring Program (PDMP) Training and Technical Assistance Center conversion data set. The authors conducted descriptive analyses for days' supply, quantity prescribed, and daily morphine milligram equivalent dose.

**Results.** The opioid prescription rate per 1,000 dental patients increased from 130.58 in 2010 to 147.44 in 2015. Approximately 68.41% of all opioids prescribed were during surgical dental visits and approximately 31.10% during nonsurgical dental visits. During nonsurgical dental visits at which dentists prescribed an opioid, most of the procedures were restorative.

**Conclusions.** Among a population of dental patients with private insurance, opioid prescribing rates in the United States increased slightly from 2010 to 2015. The largest increase was among 11-through 18-year-olds. Almost one-third of opioid prescriptions written by dentists were associated with nonsurgical dental visits.

**Practical Implications.** Use of PDMP resources and use of nonopioid analgesics could help reduce the number of opioid prescriptions in dentistry.

**Key Words.** Opioids; prescriptions; dentists.

JADA 2018;149(4):237-245

<https://doi.org/10.1016/j.adaj.2018.01.005>

The United States is facing a severe opioid addiction epidemic. In 2015, approximately 12.5 million people misused prescription opioids.<sup>1</sup> Approximately 2.1 million people misused prescription opioids for the first time, and an estimated 2 million had a prescription opioid use disorder.<sup>1</sup> Opioid overdoses caused 33,091 deaths in 2015 alone.<sup>1</sup> The amount of opioids prescribed in 2010 was 782 morphine milligram equivalents (MMEs) per capita, which decreased to 640 MME per capita in 2015.<sup>2</sup> Investigators estimated the economic burden of opioid overdose, abuse, and dependence in 2013 to be \$78.5 billion from a societal perspective.<sup>3</sup>

In 1998, dentists were the top specialty prescribers of immediate-release opioids, accounting for 15.5% of all immediate-release opioid prescriptions.<sup>4</sup> However, by 2009, the amount of opioid prescriptions written by dentists decreased to 8% of all opioid prescriptions in the United States,<sup>5</sup> and by 2012, this amount further decreased to 6.4%.<sup>6</sup> More recent and detailed data are available in some states. For example, in South Carolina during 2012 and 2013, dentists accounted for only 8.9% of all opioid prescribers but prescribed 44.9% of the initial opioids dispensed to patients.<sup>7</sup> Patients younger than 21 years received 11.2% of the total amount of opioids that dentists prescribed.<sup>7</sup> Investigators conducted a study in Indiana and used 2011 data, and their results showed that access to dentists and pharmacists increased the availability of prescription opioids and that this

Check for updates



Supplemental material is available online.



‘Approximately **31% of the opioids prescribed** for all age groups were associated with **nonsurgical dental visits...** suggests there might be opportunities to reduce opioid prescribing by targeting nonsurgical dental visit prescribing practices.’

This article has an accompanying online continuing education activity available at: <http://jada.ada.org/ce/home>.

Copyright © 2018 American Dental Association. All rights reserved.



## Opioid Analgesic Rx Table

Raymond A. Dionne, DDS, PhD

TABLE 1:

### Prescribing Options for Acute Pain to Minimize Opioid Misuse or Abuse

#### Mild Pain

OTC ibuprofen, naproxen or ketoprofen as needed.

#### Mild to Moderate Pain

Ibuprofen 400-600 mg every 4-6 hours by the clock for first 48-72 hours, not to exceed maximum recommended daily dose. As needed until pain subsides.

#### Moderately Severe Pain

Prescription dose of NSAID administered prior to the procedure or immediately afterwards. Administration of long-acting local anesthetic 0.5% bupivacaine with epinephrine for procedural anesthesia and postoperative analgesia.

*Alternative, if the above recommendation does not relieve pain sufficiently.*

Postoperative administration of prescription dose of NSAID administered by the clock for 48-72

hours combined with administration of acetaminophen 600/650 mg by the clock; the two medications can be given concurrently or alternated to maintain blood levels of both medications.

#### Severe Pain

Provide a prescription of an opioid drug in combination with acetaminophen to be filled and administered only if needed for pain not relieved by regimen for moderately severe pain.

Example: 2 tablets of 325 mg acetaminophen plus 37.5 mg tramadol (Ultracet) every 4-6 hours for pain, not to exceed 8 tablets every 24 hours.

**NB: Separate dosing of 600/650 mg acetaminophen needs to be discontinued.**

Dionne, Gordon, Moore: Compendium 2016; 37:372-378

TABLE 2:

### Comparison of Conventional Approach to Targeted Strategies

	<u>Opioid Combinations</u>	<u>Preventive/Additive/Adaptive</u>
Analgesia	++	+++
Adverse Effects	+++	+
Abuse Potential	+++	0 (without opioid) + (with tramadol) ++ (with oxycodone or hydrocodone)
Overdose Risk	++	0 (without opioid) + (with tramadol) ++ (with oxycodone or hydrocodone)

Relative effects based on well-established pharmacology of drug classes and specific agents in Table 1 ranked on a 0 to ++++ ranking.



Provided by Eastern Dentists Insurance Company (EDIC), April 2018.  
The information contained is only accurate to the day of publication and could change in the future.

## Checklist for Prescribing Opioids for Acute Dental Pain

### When Considering Opioids for Short-Term Management of Acute Pain

- ✓ Estimate pain intensity and duration associated with procedure
- ✓ If the pain is due to acute inflammation, can it be suppressed with anti-inflammatory drugs; opioids do not have any acute anti-inflammatory actions
- ✓ Inform the patient and family members of the risks of opioids: increased incidence of nausea, vomiting and drowsiness, possible risk of misuse leading to dependence, risk of death due to opioid overdose
- ✓ Evaluate the risk of harm or misuse:
  - History of substance use disorder including marijuana, alcohol, cocaine, and stimulants
  - History of mental health conditions such as depression or anxiety
  - Concurrent benzodiazepine use
  - Check the Prescription Drug Monitoring Program (PDMP) data
- ✓ Set criteria for using opioids for therapeutic intent:
  - Follow instructions for dose and dosing interval
  - No replacement for lost medications
  - Only provide a 2-3 day supply
  - No refills provided without a clinical exam
  - Discuss the greater safety of tramadol in comparison to oxycodone and hydrocodone
  - Requests for specific opioid drugs will be considered as drug seeking
  - Do not expect total pain relief, e.g., meaningful pain relief is a 50% reduction
  - Instruct the patient and family member on safe storage and disposal of opioid drugs
- ✓ Educate the patient that non-opioid drugs such as ibuprofen, naproxen and ketoprofen are more effective for post-surgical pain than opioid combination drug formulations.

### When reassessing the need for additional opioids


- ✓ Assess the need for additional opioids based on clinical exam and the usual 2-3 day time course of acute inflammatory pain
- ✓ Evaluate the risk of harm or misuse due to drug-seeking
- ✓ Check the PDMP for any other opioid prescriptions since initial visit
- ✓ Check that nonopioid medications are optimized and taken as prescribed
- ✓ Evaluate other possible causes of pain report: infection, nerve damage, alveolitis

Modified from Checklist for Prescribing Opioids for Chronic Pain, Centers for Disease Control, US Department of Health and Human Services, [www.cdc.gov/drugoverdose/prescribing/guidelines](http://www.cdc.gov/drugoverdose/prescribing/guidelines)

# Determinants of Safe, Effective, and Patient-Centered Therapeutics

Therapeutic  
Efficacy

Patient Safety  
& Needs



# Additional Information

Dionne RA, Gordon SM, Moore PA. Prescribing opioid analgesics for acute dental pain: **Time to change clinical practices in response to evidence and misperceptions.** Compendium 2016; 37:372-378.

Dionne RA, Gordon SM. Changing paradigms for acute dental pain: **Prevention is better than PRN.** California Dental Journal 2015; 43:655-662.

Dionne RA, Sanders K, Foreman R. **Analgesic prescribing in the opioid overdose epidemic.** NC Dental Gazette Spring 2018: 25-28.

Dionne RA, Warburton G, Khan A. **When are opioids indicated for postoperative analgesia in dental practice?** Compendium 2018; 39:142-143.





# Questions